Investing in biomedical discoveries
LASCCO SA is a biomedical-technology development private company based in Geneva, Switzerland. The primary objective of LASCCO is to bring promising early-stage biomedical technologies – therapeutics and diagnostics – developed in research institutes to the attention of the pharmaceutical industry.
Discover Combioxin's CAL02 against bacterial resistance broadcasted on 3sat : first-in-man clinical trial in ICU patients - 16/02/2017
Abionic receives CE Mark for most rapid sepsis diagnostic test based on PSP, moving LASCCO's biomarker to market - 09/01/2017